MRTX / Biogen, Mirati and Arcturus Reportedly on Merck's Radar

Mirati Therapeutics Inc (NASDAQ:MRTX) stock is dropping today, after news that Bristol-Myers Squibb (BMY) will acquire the company for up to $5.8 bill more_horizontal

Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity value. more_horizontal

A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics ( more_horizontal

Mirati (MRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions more_horizontal

Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down. more_horizontal

Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Ryan Asay - Vice President-Co more_horizontal

Mirati (MRTX) came out with a quarterly loss of $3.04 per share versus the Zacks Consensus Estimate of a loss of $3.23. This compares to loss of $3.18 more_horizontal

Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional m more_horizontal